5.95
price down icon4.80%   -0.30
after-market After Hours: 5.95
loading
Wave Life Sciences Ltd stock is traded at $5.95, with a volume of 2.41M. It is down -4.80% in the last 24 hours and up +1.36% over the past month. WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$6.25
Open:
$6.2
24h Volume:
2.41M
Relative Volume:
0.65
Market Cap:
$1.14B
Revenue:
$71.80M
Net Income/Loss:
$-183.59M
P/E Ratio:
-5.6436
EPS:
-1.0543
Net Cash Flow:
$-186.52M
1W Performance:
-5.85%
1M Performance:
+1.36%
6M Performance:
-58.16%
1Y Performance:
-22.73%
1-Day Range:
Value
$5.90
$6.2583
1-Week Range:
Value
$5.755
$6.47
52-Week Range:
Value
$5.02
$21.73

Wave Life Sciences Ltd Stock (WVE) Company Profile

Name
Name
Wave Life Sciences Ltd
Name
Phone
617-949-2900
Name
Address
7 STRAITS VIEW, SINGAPORE
Name
Employee
317
Name
Twitter
@WAVELifeSci
Name
Next Earnings Date
2026-07-29
Name
Latest SEC Filings
Name
WVE's Discussions on Twitter

Compare WVE vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
WVE icon
WVE
Wave Life Sciences Ltd
5.95 1.20B 71.80M -183.59M -186.52M -1.0543
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
480.25 123.19B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
663.09 69.67B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
876.25 54.58B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
183.95 39.73B 742.00K -1.37B -1.07B -7.0731
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
288.06 39.89B 4.29B 577.22M 641.34M 4.2086

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-05-26 Initiated BofA Securities Buy
Dec-12-25 Reiterated Wedbush Outperform
Dec-09-25 Upgrade RBC Capital Mkts Sector Perform → Outperform
Oct-20-25 Initiated Wells Fargo Overweight
Aug-04-25 Initiated Canaccord Genuity Buy
Jul-28-25 Initiated Oppenheimer Outperform
Jul-16-25 Initiated Citigroup Buy
Jun-11-25 Resumed Raymond James Outperform
Apr-29-25 Initiated Cantor Fitzgerald Overweight
Apr-08-25 Initiated Wedbush Outperform
Feb-25-25 Initiated Jefferies Buy
Oct-16-24 Upgrade Raymond James Outperform → Strong Buy
Sep-27-24 Resumed JP Morgan Overweight
Sep-19-24 Initiated B. Riley Securities Buy
Sep-09-24 Initiated JP Morgan Overweight
May-15-24 Initiated Wells Fargo Overweight
Dec-19-23 Upgrade Leerink Partners Market Perform → Outperform
Jul-05-23 Initiated Raymond James Outperform
May-24-23 Downgrade Jefferies Buy → Hold
Dec-15-20 Resumed H.C. Wainwright Buy
Oct-23-20 Initiated RBC Capital Mkts Sector Perform
Dec-31-19 Downgrade SVB Leerink Outperform → Mkt Perform
Nov-01-19 Initiated Guggenheim Buy
Jul-15-19 Initiated Cowen Market Perform
Apr-17-19 Reiterated H.C. Wainwright Buy
Aug-07-18 Initiated Stifel Buy
Jul-23-18 Initiated H.C. Wainwright Buy
Mar-19-18 Reiterated Mizuho Buy
Feb-15-17 Initiated H.C. Wainwright Buy
Nov-10-16 Resumed Leerink Partners Outperform
Dec-07-15 Initiated JMP Securities Mkt Outperform
Dec-07-15 Initiated Jefferies Buy
Dec-07-15 Initiated Leerink Partners Outperform
Dec-07-15 Initiated Sun Trust Rbsn Humphrey Buy
View All

Wave Life Sciences Ltd Stock (WVE) Latest News

pulisher
Jul 12, 2026

WVE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jul 12, 2026
pulisher
Jul 12, 2026

Trading the Move, Not the Narrative: (WVE) Edition - Stock Traders Daily

Jul 12, 2026
pulisher
Jul 11, 2026

WVE Stock Edges Up After Positive Early Data For Rare Disease Drug - Stocktwits

Jul 11, 2026
pulisher
Jul 11, 2026

WVE Technical Analysis & Stock Price Forecast - Intellectia AI

Jul 11, 2026
pulisher
Jul 10, 2026

ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits

Jul 10, 2026
pulisher
Jul 10, 2026

Has Wave Life Sciences (WVE) Fallen Far Enough To Look Fairly Valued? - Sahm

Jul 10, 2026
pulisher
Jul 08, 2026

Wave Life Sciences (WVE) Jefferies London Healthcare Conference 2025 Summary - Quartr

Jul 08, 2026
pulisher
Jul 07, 2026

Wave Life Sciences court hearing set for July 14 on redomiciliation - Investing.com

Jul 07, 2026
pulisher
Jul 07, 2026

Wave Life Sciences court hearing set for July 14 on redomiciliation By Investing.com - Investing.com South Africa

Jul 07, 2026
pulisher
Jul 07, 2026

Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation - The Manila Times

Jul 07, 2026
pulisher
Jul 06, 2026

What Went Wrong For WVE? The Obesity Drug Trial Data That Spooked Investors - Stocktwits

Jul 06, 2026
pulisher
Jul 05, 2026

Wave Life Sciences (WVE) Is Up 7.4% After Advancing RNA-Based Obesity Drug Into Phase 2a Trial - simplywall.st

Jul 05, 2026
pulisher
Jul 02, 2026

Is Wave Life Sciences (WVE) Undervalued On Its New Obesity Trial Progress? - simplywall.st

Jul 02, 2026
pulisher
Jul 01, 2026

Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect? - Yahoo Finance

Jul 01, 2026
pulisher
Jul 01, 2026

Jessica Chen - White & Case LLP

Jul 01, 2026
pulisher
Jun 30, 2026

(WVE) Volatility Zones as Tactical Triggers - Stock Traders Daily

Jun 30, 2026
pulisher
Jun 30, 2026

Wave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM Trial - Insider Monkey

Jun 30, 2026
pulisher
Jun 28, 2026

Price to earnings forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

7 Singapore Companies That Have Listed On Nasdaq And Where They Are Now - DollarsAndSense.sg

Jun 28, 2026
pulisher
Jun 27, 2026

Does Wave Life Sciences’ (WVE) RNA Obesity Program Signal a Shift in Its Competitive Positioning? - simplywall.st

Jun 27, 2026
pulisher
Jun 27, 2026

Enterprise value to EBITDA forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Price to sales forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView

Jun 27, 2026
pulisher
Jun 26, 2026

Enterprise value to EBIT forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to book forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to book forward of Wave Life Sciences Ltd. – DUS:1U5 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Wave Life Sciences (WVE) shareholders approve Singapore Scheme for redomiciliation - Stock Titan

Jun 26, 2026
pulisher
Jun 26, 2026

We Think Wave Life Sciences (NASDAQ:WVE) Can Afford To Drive Business Growth - Moomoo

Jun 26, 2026
pulisher
Jun 26, 2026

Price to earnings forward of Wave Life Sciences Ltd. – DUS:1U5 - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

Wave Life Sciences(WVE) Stock Options Chain | Quotes & News - Moomoo

Jun 25, 2026
pulisher
Jun 25, 2026

Wave Life Sciences Ltd. Actuals & Estimates (NASDAQ:WVE) - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

WVE Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Wave Life Sciences initiates phase 2a obesity trial for WVE-007 By Investing.com - Investing.com Australia

Jun 25, 2026
pulisher
Jun 25, 2026

Wave Life Sciences initiates phase 2a obesity trial for WVE-007 - Investing.com UK

Jun 25, 2026
pulisher
Jun 24, 2026

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT Trial of WVE-007 for Obesity and Cardiometabolic Diseases - Investing News Network

Jun 24, 2026
pulisher
Jun 24, 2026

Wave Life Sciences Ltd. (WVE) stock price, news, quote and history - Yahoo Finance Australia

Jun 24, 2026
pulisher
Jun 24, 2026

Wave Life Sciences (WVE) Advances Phase 2a Clinical Trial for WV - GuruFocus

Jun 24, 2026
pulisher
Jun 24, 2026

Wave Life Sciences Starts Phase 2 Trial of Obesity Drug - Moomoo

Jun 24, 2026
pulisher
Jun 24, 2026

Wave Life Sciences Initiates Phase 2a of INLIGHT Trial of WVE-007 for Obesity, Reporting Sustained Visceral Fat Reduction in Phase 1 Data - Quiver Quantitative

Jun 24, 2026
pulisher
Jun 24, 2026

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases - The Manila Times

Jun 24, 2026
pulisher
Jun 24, 2026

Wave Life Sciences Announces Initiation of Phase 2a Portion - GlobeNewswire

Jun 24, 2026
pulisher
Jun 19, 2026

Price-Driven Insight from (WVE) for Rule-Based Strategy - Stock Traders Daily

Jun 19, 2026
pulisher
Jun 19, 2026

The Bull Case For Wave Life Sciences (WVE) Could Change Following A Zacks Earnings-Estimate Upgrade - simplywall.st

Jun 19, 2026
pulisher
Jun 18, 2026

WAVE LIFE SCIENCES LTD (WVE) Stock Chart - ChartMill

Jun 18, 2026
pulisher
Jun 18, 2026

WAVE Life Sciences Ltd (WVE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

WAVE Life Sciences Ltd (WVE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

WAVE Life Sciences Ltd (WVE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

WAVE Life Sciences Ltd (WVE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 17, 2026

Wave Life Sciences Ltd Stock (WVE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Wave Life Sciences Ltd Stock (WVE) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
RA CAPITAL MANAGEMENT, L.P.
Director
Mar 27 '26
Buy
6.43
2,495,623
16,046,856
26,004,414
RA CAPITAL MANAGEMENT, L.P.
Director
Mar 30 '26
Buy
6.50
971,091
6,312,092
26,975,505
Francis Chris
See Remarks
Feb 26 '26
Option Exercise
4.28
33,194
141,920
79,767
Francis Chris
See Remarks
Feb 26 '26
Sale
15.05
33,194
499,593
61,867
Moran Kyle
Chief Financial Officer
Feb 09 '26
Sale
13.45
3,588
48,259
134,385
BOLNO PAUL
President and CEO
Feb 09 '26
Sale
13.45
10,480
140,956
275,520
Francis Chris
See Remarks
Feb 09 '26
Sale
13.45
1,883
25,326
61,867
Vargeese Chandra
See Remarks
Feb 09 '26
Sale
13.45
3,228
43,417
408,246
$109.14
price down icon 5.60%
$34.51
price down icon 4.06%
$56.45
price up icon 0.04%
$67.01
price down icon 1.85%
ONC ONC
$303.96
price up icon 1.76%
$288.06
price down icon 3.58%
Cap:     |  Volume (24h):